Building resilience needs to be central to treating drug-resistant TB

A study published in The Lancet Global Health described distinct stages through drug-resistant TB (DR-TB) diagnosis and treatment from the point of view of patients with DR-TB and HIV in KwaZulu-Natal province, South Africa. The study emphasised that despite improvements in treatment, including shorter, all-oral regimens that include bedaquiline, DR-TB treatment remains lengthy, difficult, and life-changing for individuals.